INTRODUCTION
Allergic asthma is caused by an inappropriate adaptive T helper 2 (Th2) cell-mediated immune response to innocuous antigen, leading to eosinophilic airway inflammation, mucus hypersecretion, structural changes to the airway wall, and variable airway obstruction (Barnes, 2008) . The cytokines produced by allergen-specific Th2 cell-type lymphocytes are held largely responsible for orchestrating the many features of asthma. Sensitization results from allergen recognition by structural cells of the airways and innate immune cells like basophils and dendritic cells (DCs) that induce and amplify adaptive Th2 cell-mediated immune responses (Barrett and Austen, 2009; Hammad et al., 2009 Hammad et al., , 2010 Lambrecht and Hammad, 2009; Sokol et al., 2008 ). The precise molecular mechanisms involved in allergenicity and Th2 cell response induction by DCs are incompletely understood (Paul and Zhu, 2010) . Allergens have a complex molecular structure and often display enzymatic activity that stimulates epithelial and innate immune cells through protease-activated receptors (Hammad and Lambrecht, 2008; Sokol et al., 2008; Tang et al., 2010) , whereas others like house dust mite (HDM) contain endotoxin or other pathogen-associated microbial patterns (PAMPS) that trigger epithelial cells and/or DCs in a toll-like receptor 4 (TLR4)-or C-type lectin receptor-dependent manner Nathan et al., 2009; Trompette et al., 2009) . Triggering of PAMP receptors on epithelial cells and/or basophils subsequently leads to release of innate proTh2 cell cytokines like thymic stromal lymphopoietin (TSLP), granulocyte-macrophage colony stimulating factor (GM-CSF), IL-25, and IL-33 that instruct DCs to promote Th2 cell-type immunity in the mediastinal lymph nodes (Hammad and Lambrecht, 2008; Hammad et al., 2009 Hammad et al., , 2010 Rank et al., 2009; Sokol et al., 2008; Zhou et al., 2005) .
Although contamination of allergens with PAMPs that stimulate pattern recognition receptors provides a good explanation for how immunity can be induced to harmless allergens, another could be that allergens trigger release of damage-associated molecular patterns (DAMPs) that occur intracellularly in homeostasis but are released extracellularly upon physical or metabolic stress (Matzinger, 2002) . A well-known DAMP is uric acid (UA) released from dying or stressed cells (Shi et al., 2003; Vorbach et al., 2003) . Uric acid crystals potently trigger acute neutrophilic inflammation through stimulation of the NLRP3 inflammasome and release of interleukin-1b (Chen et al., 2006; Martinon et al., 2006) . This pathway is at the heart of gouty inflammation, as supported by the absence of UA-induced neutrophilic inflammation in mice lacking the NLRP3, ASC (Pycard), IL-1R, or its downstream adaptor MyD88 and by the success of IL-1 receptor antagonist (IL-1RA) treatment for gout. We have reported recently that UA is released in the peritoneal cavity after injection Figure 1 . UA Is Necessary and Sufficient for Th2 Cell Response Induction to Ovalbumin (A) In vitro bone marrow-derived GM-CSF-cultured DCs were stimulated with OVA or OVA+alum in the presence or absence of uricase (0.1 U/ml). In vivo, OVA or OVA+alum with or without 50 U uricase was injected intraperitoneally (i.p.). Bioactive IL-1b was measured in the supernatant or the peritoneal lavage 2 hr after exposure.
of the Th2 cell adjuvant aluminum hydroxide or alum, commonly coinjected with harmless antigens intraperitoneally to induce allergic sensitization and asthma (Kool et al., 2008b) . In addition to inducing release of UA, alum can also directly trigger the NLRP3 inflammasome and stimulate secretion of bioactive IL-1b (Eisenbarth et al., 2008; Kool et al., 2008a; Li et al., 2008; McKee et al., 2009 ). These studies have aroused interest in the UA-inflammasome-IL-1 axis as a trigger of Th2 cell development.
Here, we hypothesized that uric acid is a general inducer and amplifier of Th2 cell immunity. By using models of intraperitoneal injection, as well as airway exposure of HDM allergen in mice and patients, we found that UA is present at sites of Th2 cell development, where it is necessary and sufficient for induction of Th2 cell immunity. Contrary to expectation, this Th2 cell adjuvant effect did not require triggering of the NLRP3-ASC complex, nor signaling through the IL-1R. Rather, UA induced Th2 cell immunity by triggering DC activation in a spleen tyrosine kinase (Syk)-and PI3-kinase d-dependent manner. These findings identify UA as an unexpected initiator and amplifier of Th2 cell immunity and allergic inflammation.
RESULTS

Uric Acid Is Necessary and Sufficient for Induction of Th2 Cell Immunity to Harmless Antigen
We have reported that UA is released in the peritoneal cavity after injection of alum (Kool et al., 2008b) and is a necessary intermediate for early DC activation in vivo, whereas others argued that the immunostimulatory effects of alum did not require UA (Franchi and Nú ñ ez, 2008) . As shown in Figure 1A , the degradation of UA by uricase treatment reduced secretion of bioactive IL-1b into the peritoneal cavity, whereas production of IL-1b by DCs in vitro did not require endogenous release of UA. Therefore, the important role of UA in mediating the adjuvant activity of alum is mainly revealed in vivo. The increased UA production after injection of OVA in alum was found to be intact in Tlr4
, and Casp1 À/À mice, excluding an important role for the TLR4 or inflammasome-IL1b axis in its induction ( Figure S1 available online). Because alum is frequently used to induce allergy in animal models of asthma, we hypothesized that UA is necessary for promoting adaptive Th2 cell immunity to OVA+alum. Injection of OVA+alum into BALB/c mice led to an increased concentration of UA in the peritoneal cavity, which could be neutralized by treatment with uricase ( Figure 1B ). Uricase treatment during priming to OVA+alum eliminated Th2 cell-dependent bronchoalveolar lavage (BAL) fluid eosinophilia ( Figure 1C ), peribronchial inflammation and goblet cell hyperplasia ( Figure 1D ), secretion of IL-5 in the BAL fluid ( Figure 1E ), production of IL-4, IL-5, IL-10, and IL-13 (but not IFN-g) in mediastinal LN (MLN) cultures restimulated with OVA antigen for 3 days ex vivo ( Figure 1F ), and production of serum OVA-specific IgE and IgG1 ( Figure 1G ). There was also a trend toward reduced production of IgG2a by uricase treatment. OVA+alum injection also led to release of extracellular ATP, another DAMP known to activate the NLRP3 inflammasome via the P 2 X 7 receptor (Mariathasan et al., 2006) and promote Th2 cell immunity (Idzko et al., 2007 ), yet its neutralization or use of P2rx7 À/À mice did not reveal a contribution to Th2 cell immunity ( Figure S2 ). To address whether UA was also sufficient to induce Th2 cell immunity, we injected OVA admixed with UA crystals. Compared with control mice receiving OVA, this treatment dose dependently increased airway eosinophilia ( Figures 1H and 1I ), goblet cell hyperplasia ( Figure 1I ), IL-5 in BAL fluid ( Figure 1J ), and production of OVA-specific IgE, IgG1, and IgG2a ( Figure 1K ). Injection of OVA+UA also led to increased production of IL-4, IL-5, and IL-10, but not IFN-g, in MLN cells (data not shown). These responses were of similar strength as those induced by injection of OVA+alum ( Figures 1C-1E ). Therefore, UA is necessary and sufficient for Th2 cell response development to intraperitoneal injection of harmless antigen, identifying it as a potent Th2 cell adjuvant.
Endogenous UA Is Necessary for Development of Th2 Cell Immunity to HDM Allergen in the Absence of Adjuvant We next investigated the involvement of endogenous UA in response to complex and relevant allergens in the airways. A single intranasal HDM administration in naive mice resulted in a rapid increase in UA concentration in BAL fluid and lung (Figure 2A) compared with PBS. Mice sensitized and challenged with HDM developed features of allergic asthma, like BAL fluid and lung eosinophilia, lymphocytosis, goblet cell hyperplasia ( Figures 2B and 2D) , and airway hyperresponsiveness (AHR) to increasing doses of metacholine ( Figure 2C ). Intratracheal administration of uricase on day 0 at the time of sensitization neutralized the increase in UA (Figure 2A ) and strongly reduced airway lymphocytosis and eosinophilia and AHR (Figures 2A-2D ). To explain the mechanism of action, we evaluated the production of cytokines known to promote eosinophilic inflammation and Th2 cell immunity (Hammad and Lambrecht, 2008; Saenz et al., 2008) . As already reported, the concentration of GM-CSF, TSLP, and IL-25 ( Figure 2E ) were increased in the lungs of animals exposed to a single HDM injection, compared with PBS ). However, this innate cytokine response was severely reduced in mice treated with uricase. House dust mite-driven Th2 cell development relies on antigen presentation by inflammatory Ly6C hi CD11b + DCs that take up antigen in the lung and migrate to the MLN (Hammad et al., 2010) . To address antigen uptake and migration of these inflammatory DCs, we injected fluorescent OVA together with HDM allergen. In mice injected with OVA+HDM, migratory DCs carrying fluorescent cargo were easily identified in the MLN. After uricase treatment, this migration was strongly reduced ( Figure 2F ). We next searched for the source of increased UA production. Within 2 hr after HDM administration, there was increased immunoreactivity for UA in airway epithelial cells and major histocompatibility complex II (MHCII)-positive alveolar macrophages and recruited monocytes (Figures 2G) compared to mice administered PBS. Strong UA immunoreactivity was seen along the basement membrane of HDM-exposed mice. Although UA release occurs in response to necrotic cell death, UA is also produced as a pulmonary defense mechanism to oxidative damage, through increased xanthine oxidoreductase (XOR) enzyme activity inside peroxisomes (Vorbach et al., 2003) . In bronchial epithelial cells and MHCII-positive cells, HDM exposure induced enhanced staining for the 70 kDa peroxisomal marker PMP70, suggestive of peroxisomal biogenesis ( Figure 2H ; Imanaka et al., 1999) . The expression of XOR was increased in BAL cells of HDM-exposed mice 2 hr after instillation compared with PBS ( Figure 2I ). We ) and others (Phipps et al., 2009; Trompette et al., 2009 ) recently identified TLR4 signaling as a crucial early trigger for the innate pro-Th2 cell immune response to allergens. In contrast to the alum-induced increase of UA in the peritoneal lavage ( Figure S1 ), HDM-driven production of UA was severely reduced in C57BL/6 Tlr4 À/À mice ( Figure 2J ), suggesting that triggering of TLR4 by HDM is necessary for activation of XOR and UA production in the airways in response to allergens.
Uric Acid Is Increased in Allergen-Challenged Human Asthmatics and Mice
To study whether our findings had any bearing on human asthma, BAL fluid was collected from 21 asthmatic subjects, 10 min and 24 hr after segmental challenge with saline or specific allergens (rye, birch, or HDM). There was no difference in the concentration of UA between saline-and allergen-challenged segments after 10 min. In contrast, 24 hr after allergen provocation, the UA concentration was markedly elevated in the BAL fluid from allergen-compared to saline-challenged segments ( Figure 3A ). This increase in UA concentration correlated with the influx of eosinophils and lymphocytes into the BAL ( Figures  3B and 3C ). Subgroup analysis of patients showing a minor rise in UA showed that this was not correlated with the type of allergen used nor the concentration of IgE in the serum, but rather on maintenance inhaled corticosteroid (ICS) therapy up to 7 days prior to allergen challenge ( Figure S3 ). To test whether UA neutralization would have any therapeutic potential, we again turned to the mouse model of HDMinduced asthma. Mice were first sensitized to HDM and were treated with uricase prior to each allergen challenge. HDM challenge induced a rise in UA in BAL fluid, still measurable 3 days after the last of five challenges ( Figure 3D ), and uricase treatment during challenge reduced airway eosinophilia (Figure 3E ), metacholine-induced AHR, and IL-13 concentration in the BAL fluid ( Figures 3F and 3G ). Allergen challenge induced high numbers of eosinophils in the BAL fluid, which indicates that cellular death of recruited eosinophils could be a trigger for UA production. Uricase treatment had similar effects in a milder sensitization model in which only 20% of the number of eosinophils was recruited compared with the high dose sensitization model ( Figure S4 ), arguing against the idea that UA plays a role only when there would be massive cellular recruitment and death.
UA Crystals, Alum, and HDM Promote Th2 Cell Immunity in the Absence of NLRP3 Inflammasome Activation Although UA is the prototypical activator of the NLRP3 inflammasome and several groups (Eisenbarth et al., 2008; Franchi and Nú ñ ez, 2008; Hornung et al., 2008; Kool et al., 2008a; McKee et al., 2009 ) have shown that alum directly triggers NLRP3 in vitro, there is considerable controversy whether the (B) Mice were sensitized i.n. on day 0 with PBS, HDM, or HDM+uricase and challenged i.n. with HDM on days 7-11. On day 14, BAL was examined for the presence of eosinophils and lymphocytes. Immunity Uric Acid as a Trigger of Th2 Cell Immunity inflammasome-IL-1b pathway is necessary for adjuvanticity in vivo (Franchi and Nú ñ ez, 2008; Williams et al., 2010 Th2 cell-dependent asthmatic airway inflammation developed normally in Nlrp3 À/À mice immunized with OVA+alum (Figure S5 ). To address whether HDM-driven asthma was dependent on these pathways, Nlrp3
, and P2rx7 À/À mice were sensitized and challenged with HDM via the airways but showed no reduction in Th2 cell-dependent eosinophilia ( Figure S6 ). As already reported, Myd88 À/À and Tlr4 À/À mice had reduced HDM-driven airway inflammation (data not shown; Hammad et al., 2009 Hammad et al., , 2010 . In conclusion, the prototypical Th2 cell stimuli alum and HDM, like UA crystals, do not rely on the NLRP3 inflammasome to induce Th2 cell-adaptive immunity leading to allergic airway inflammation. DCs that had ingested OVA in the peritoneal cavity compared with mice injected with OVA-AF647 alone ( Figure 5A ), and these recruited cells had higher expression of the costimulatory molecule CD86 ( Figure 5B ). Although recruitment and activation of DCs suggests a functional role for these cells in the UA effect, we still wanted to address whether DCs are really necessary for mediating Th2 cell immunity, because recent work suggested that DCs are poor inducers of Th2 cell immunity, whereas basophils readily are (Perrigoue et al., 2009; Sokol et al., 2009; Yoshimoto et al., 2009 ). We therefore injected OVA+UA in Cd11c-DTR C57BL/6 mice, together with diphteria toxin (DT) to deplete DCs (Jung et al., 2002) . DT injection in Tg mice abolished airway eosinophilia induced by OVA+UA ( Figure 5D ). This effect was also seen when we injected an antibody to Ly6C/G (Gr1) that depletes inflammatory monocytes ( Figure 5C ), but in this setting one cannot exclude that neutrophils play an additional role. To finally demonstrate that inflammatory DCs are sufficient to induce Th2 cell immunity, we injected GM-CSF-cultured OVApulsed DCs (a model to generate inflammatory type DCs) into the peritoneal cavity, followed by OVA challenge to the lung. Intraperitoneal injection of OVA-pulsed DCs, but not unpulsed DCs, was able to prime for an eosinophilic Th2 cell response (C) C57BL/6 mice were treated with Gr-1 or control antibodies (500 mg/mouse) on day À1, 0, 1, 2. On day 0, mice were treated with OVA mixed or not with UA crystals (UA), boosted on day 7 with OVA i.p., and challenged with OVA aerosols on days 17-19. Cellular composition in the BALf is shown. (D) C57BL/6 Cd11c-DTR mice were treated with diphtheria toxin (100 ng/mouse i.p.) on day À1. On day 0, mice were treated with OVA mixed or not with UA crystals, boosted on day 7 with OVA i.p., and challenged with OVA aerosols on days 17-19. Cellular composition in the BALf was determined by flow cytometry. (E) BALB/c mice were sensitized by intratracheal instillation of 1 3 10 6 unpulsed or OVA-pulsed bone marrow-derived GM-CSF DCs with or without uricase.
UA Crystals Recruit Inflammatory DCs that
On days 10-12, mice were challenged with OVA aerosols. Cellular composition in the BAL is shown. Data are shown as mean ± SEM, *p < 0.05, **p < 0.01, n = 4-6 mice/group. Experiments were repeated 2-3 times. Data shown are representative of all experiments.
( Figure 5E ). However, treatment with uricase did not inhibit Th2 cell development induced by DC injection, demonstrating that the immunostimulatory effects of UA are upstream of DC activation in vivo. These experiments also demonstrate that uricase treatment does not have a generalized off-target suppressive effect on Th2 cell polarization, but rather inhibits inflammatorytype DC recruitment and activation.
UA Activates DCs and Th2 Cell Immunity in a Syk-and PI3-Kinase d-Dependent Manner
The above data implied that DCs are a crucial intermediate cell type in mediating the Th2 cell immune response to OVA+UA (Figure 5) but also that the NLRP3-ASC-IL1-R axis were not involved in this process in vivo (Figure 4) . UA crystals mixed with OVA in vitro were able to induce the secretion of bioactive cleaved IL-1b in inflammatory DCs, and this effect was completely absent in cells of Nlrp3 À/À mice, essentially showing that UA does trigger this inflammasome pathway in DCs. However, OVA+UA also induced secretion of IL-6 and TNF-a in inflammatory DCs and these responses were not abolished in Nlrp3
mice. Strikingly, OVA+UA did not induce production of the Th1 cell instructive cytokine IL-12. Recently, via atomic force microscopy, UA crystals were shown to directly engage cholesterolrich cellular membranes of DCs in a receptor-independent manner, leading to recruitment and activation of spleen tyrosine kinase (Syk) on membrane-associated immunoreceptor tyrosine activation motifs (Ng et al., 2008) . Other studies have also identified Syk signaling and downstream PI3-kinase activation as an essential intermediate of UA-induced human neutrophil activation (Desaulniers et al., 2001; Popa-Nita et al., 2007) . When the in vitro Syk inhibitor piceattanol was added, UA+OVA no longer induced IL-1b, IL-6, or TNF-a production in inflammatory DCs, suggesting that this pathway was more broadly involved in inducing cytokine production in DCs ( Figure 6A ). Oral administration of the Syk inhibitor BAY61-3606 reduced influx of OVA-positive inflammatory Ly6C + CD11b + monocytes in the peritoneum 24 hr later ( Figure 6B ). Signaling downstream of Syk has been shown to involve interaction of p85 with p110d subunits of PI3-kinase (Popa-Nita et al., 2007) . The number of OVA + Ly6C + CD11b + monocytes 24 hr after injection of OVA+UA was strongly reduced in mice expressing a catalytically inactive form of the p110d subunit of PI3-kinase (D910A) ( Figure 6C ). We finally addressed whether Syk and downstream PI3-kinase d signaling was important for development of adaptive Th2 cell immunity to OVA+UA. Oral administration of BAY61-3606 compound strongly reduced airway lymphocytosis and eosinophilia ( Figure 6D ). Accordingly, OVA+UA did not induce Th2 cell immunity in Pik3cd D910A mice ( Figure 6E ), although this finding could also reflect effects on other cells like mast cells (Ali et al., 2004) . To address whether the inibition of Syk was specifically acting at the level of DCs, we took a genetic approach and immunized Cd11cCre 3 Sykb fl/fl mice specifically lacking Syk in CD11c hi cells (unpublished observations) or control mice with OVA or OVA+UA crystals. Upon OVA challenge, the degree of reduction in airway eosinophilia in these Sykb À/À DC mice was of similar magnitude as those treated with a pharmacological Syk antagonist, suggesting indeed that Syk triggering in DCs is crucial for mounting Th2 cell immunity to UA ( Figure 6F ).
DISCUSSION
Although UA is a known trigger for acute neutrophilic inflammation (Martinon et al., 2006) , we here identified its role as a promotor of Th2 cell-dependent allergic inflammation. The release of UA was seen in patients with allergic asthma challenged with relevant allergen, in naive and sensitized mice exposed to the prototypical Th2 cell inducer and relevant HDM allergen, and after injection of the prototypical Th2 cell adjuvant alum. The Th2 cell-inducing capacity of UA occurred independently from its actions on the NLRP3-ASC-IL-1-MyD88 axis. UA is released upon alum administration in vivo, but not in vitro, so these findings could explain the controversy that has arisen as to whether triggering NLRP3 inflammasome activation is crucial for alum adjuvanticity ). All authors that have studied the involvement of NLRP3 agree that NLRP3, PYCARD (ASC), and caspase-1 are crucial for alum-induced IL-1b secretion in vitro and in vivo, but this does not automatically imply that all adjuvant effects of alum must therefore occur via this pathway (Franchi and Nú ñ ez, 2008; Li et al., 2007 Li et al., , 2008 McKee et al., 2009) . Our findings suggest that UA released upon alum injection in vivo is by itself sufficient to induce Th2 cell adjuvant effects that do not depend on the inflammasome-IL-1R pathway. It has indeed long been known that alum-induced asthma models do not rely on IL-1R signaling (Piggott et al., 2005; Schmitz et al., 2003) nor on the downstream essential adaptor molecule MyD88 (Piggott et al., 2005) . One report has suggested that Nlrp3 is absolutely required for alum to induce Th2 cell immunity to OVA and subsequent development of allergic type inflammation of the lung (Eisenbarth et al., 2008) , at odds with findings in the current report. These authors, however, also demonstrated that the effects of alum were MyD88 independent, arguing against a role for IL-1R signaling, given the crucial role of MyD88 as a signaling intermediate of the IL-1R pathway. These differences could be explained best by subtle differences in antigens used, type of alum used, and timing of analysis. Also we have described previously that NLRP3, IL-1, and MyD88 are involved in the early innate response of DCs to alum injection in the peritoneal cavity, but clearly these reactions are redundant with other pathways to induce Th2 cell immunity to OVA (Figure 4) , and their elimination never leads to complete abolition of DC activation or subsequent T cell activation (Kool et al., 2008a (Kool et al., , 2008b .
The most striking finding of our paper is that UA is also released upon primary exposure of the lung to HDM, as well as upon allergen challenge in already sensitized human asthmatics and mice. Experiments with the UA-degrading enzyme uricase furthermore showed that endogenously released UA promotes Th2 cell sensitization by amplifying the production of innate pro-Th2 cytokines that instruct DCs to induce Th2 cell immunity, like TSLP, GM-CSF, and IL-25 (Barrett and Austen, 2009; Lambrecht and Hammad, 2009) , as well as stimulating the activation of inflammatory DCs. Many reported that this innate pro-Th2 cytokine release and DC activation depends on TLR4 triggering on lung epithelial cells via endotoxin contained in the HDM allergen (Hammad et al., , 2010 Trompette et al., 2009) . We now show that TLR4 triggering is functionally connected to the induction of UA production in epithelial cells and macrophages. Most probably this occurs via induction of the enzymatic activity of the rate-limiting uric acid-synthesizing enzyme xanthine oxidoreductase, leading to production of UA inside peroxisomes. Alternatively, increased UA concentration could also result from reduced catabolism from urate oxidase. Although we have not formally investigated the mechanisms of TLR4-driven induction of UA production, it is known that UA is found in the lining fluid of the airway epithelial layer in vivo and is induced in response to various types of oxidative stress like ozone exposure or respiratory viral infection (Akaike et al., 1990; Papi et al., 2008) . The xanthine oxidoreductase gene is À/À mice and preincubated with the Syk inhibitor piceatennol for 30 min (50 mM), then pulsed with OVA (100 mg/ml) with or without UA crystals (250 mg/ml) for 3 hr, after which cytokine concentration was determined in the cell supernatant. (B) C57BL/6 mice were treated twice a day on days À1 and À2 orally with the specific Syk inhibitor BAY61-3606 (Yamamoto et al., 2003) and injected on day 0 with OVA-AF647 mixed or not with UA crystals intraperitoneally (i.p.). 24 hr later, the peritoneal lavage was examined for the presence of OVA + inflammatory monocytes.
(C) Pik3cd D910A or WT C57BL/6 mice were injected with OVA-AF647 mixed or not with UA crystals (UA) i.p., and 24 hr later the peritoneal lavage was examined for the presence of OVA + inflammatory monocytes.
(D) C57BL/6 mice were treated twice a day on days À1 and À2 orally with the specific Syk inhibitor BAY61-3606 . On day 0, mice were treated with OVA mixed or not with UA crystals, boosted on day 7 with OVA i.p., and challenged with OVA aerosols on days 17-19. Cellular composition in the BAL is shown.
(E) Cellular composition in the BALf of WT and Pik3cd D910A mice, which have been sensitized with OVA+UA crystals and challenged with OVA aerosol as decribed in (D), is depicted.
(F) Cellular composition in the BAL of Sykb À/À DC and Sykb +/+ DC chimeric mice, which were sensitized with OVA+UA crystals and challenged with OVA as described in (D). Data are shown as mean ± SEM, *p < 0.05, **p < 0.01, n = 4-6 mice/group, representative of at least two experiments per panel.
induced as part of an innate immune response to various stimuli like LPS, tissue hypoxia, and early innate cytokines like IL-1, and the promotor region contains an NF-kB control element (Hassoun et al., 1998; Vorbach et al., 2003) . How exactly locally released UA affects the innate cytokine production by epithelial cells is at present unclear, nor do we have any indication that UA concentration would be so high that UA crystals are formed in the lung lining fluid. Because of physicochemical constraints, we have been unable to transfer UA crystals to the lungs of mice to directly probe for effects on epithelial cells without mortality of the mice. One possiblility that needs further exploration is the fact that the antioxidant properties of UA in the lung lining fluid affect the potential of bronchial epithelial cells to synthesize, correctly fold, and secrete proteins, processes sensitive to oxidative stress (Santos et al., 2009 ).
We have also reported previously that ATP is released in the airways of OVA-challenged sensitized mice, as well as allergen-challenged patients, indicating that a DAMP can contribute to asthma pathogenesis (Idzko et al., 2007) . Because ATP is a well-known activator of the NLRP3 inflammasome (Franchi et al., 2007) , acting via the P2X7 purinergic receptor that is a potassium efflux channel, it made sense to address whether either alum-induced or HDM-induced asthma relied on P2X7. Experiments in P2rx7 À/À mice did not, however, reveal a crucial role of this receptor in asthma development, again arguing against a predominant role of NLRP3 in asthma. However, there are many ways by which ATP can activate innate and structural cells of the lung to promote asthma and Th2 cell development, because the purinergic receptor family is very broad and widely expressed among others on eosinophils (Kobayashi et al., 2010) . Recently, several groups studying Th2 cell response induction to the protease allergen papain or to gastrointestinal parasites have reported that DCs are poor inducers of Th2 cell immunity that are neither sufficient nor required for Th2 lymphocyte differentiation, basophils being clearly superior (Perrigoue et al., 2009; Sokol et al., 2009; Yoshimoto et al., 2009 ). However, it was recently also shown that for HDM sensitization, inflammatory DCs are the antigen-presenting cells that provide the first instruction to Th2 cell development, whereas basophils act to enhance these responses (Hammad et al., 2010) . Given the fact that the relative contribution of DCs versus basophils seems to depend on the type of Th2 cell stimulus or the route of injection (Tang et al., 2010) , it was therefore of interest to study the involvement of DCs in mediating the Th2 cell adjuvant activities of UA injected into the peritoneal cavity. Employing the logic of Koch's postulates, we first found that inflammatory type DCs and their monocytic precursors were recruited to the site of UA injection, that depletion of CD11c hi dendritic cells abolished UA-driven Th2 cell responses, and that adoptive transfer of inflammatory DCs to the peritoneal cavity was sufficient to induce Th2 cell immunity. Moreover, because we did not observe basophil recruitment to the draining lymph nodes of the peritoneal cavity (data not shown), we believe that these experiments are sufficient proof that DCs are the cells driving Th2 cell immunity to OVA+UA. Recently, UA crystals were shown to directly engage cholesterol-rich cellular membranes of DCs in a receptor-independent manner, leading to activation of Syk and downstream PI3K signaling (Ng et al., 2008) . Experiments with in vitro and in vivo Syk inhibitors, as well as kinase-dead Pik3cd D910A mice, revealed that this pathway was relevant for early in vivo recruitment of inflammatory DCs to the site of injection and in vivo development of Th2 cell immunity to OVA+UA. Although these manipulations could also affect other cells, the use of mice specifically lacking Syk expression in DCs allowed us to conclude that at least the DC is a predominant sensor of UA crystals. How exactly DCs exposed to UA subsequently polarize Th2 cell immune responses is more speculative, but again probably involves Syk signaling. We observed that DCs exposed to OVA+UA produced IL-1b, IL-6, and TNF-a in the absence of the polarizing cytokine IL-12, in a Syk-dependent manner. We and others have previously reported that absence of IL-12 production is a prerequisite for inflammatory DCs to be able to induce Th2 cell immunity, because retroviral overexpression of IL-12 abolishes DC-driven Th2 cell development and subsequent asthma (Eisenbarth et al., 2002; Kuipers et al., 2004) , whereas others reported that IL-6 and TNF-a are all involved in promoting DC-driven Th2 cell development in asthma (Dodge et al., 2003; Ebeling et al., 2007; Eisenbarth et al., 2002; Rincó n et al., 1997) . One report demonstrated that Syk signaling in DCs is crucial for Th2 cell-dependent asthma development driven by adoptive transfer of DCs, but it is unclear how this relates to polarizing cytokine secretion (Matsubara et al., 2006) . Further definitive experiments will involve neutralization of individual cytokines to address these issues in detail.
In conclusion, we have identified an unexpected role for UA as a crucial initiator and amplifier of Th2 cell immunity and allergic inflammation in the mouse by activating inflammatory DCs. At the same time we have identified a pathway of immune activation by UA crystals that is independent of their well-known capacity to trigger the NLRP3 inflammasome. The fact that neutralization of uric acid at the time of allergen challenge reduces the salient features of asthma, and the fact that increased UA concentrations are found in patients after allergen challenge, open up the prospects that this pathway could be used for novel therapeutics in asthma.
EXPERIMENTAL PROCEDURES Human Subjects
Twenty-one nonsmoking patients with mild allergic asthma (Table S1) were recruited based on airway hyperresponsiveness, positive allergen skin prick tests, elevated total or specific IgE concentrations, and a dual reaction after allergen challenge (Lommatzsch et al., 2006) . The calculation of the individual provocation dose was performed based on responsiveness to inhalation allergen challenge (Lommatzsch et al., 2006) . Inhaled and segmental allergen challenges were separated by at least 4 weeks. Segmental allergen challenge was performed as described (Lommatzsch et al., 2006) . Corticosteroids were withdrawn at least 7 days before challenge. Patients gave their written informed consent, and he study was approved by the local ethics committee of the University Hospital Rostock, Germany.
Mice BALB/c mice and C57BL/6 mice (6-9 weeks old) were purchased from Harlan (Zeist, The Netherlands). Nalp3
, and WT C57BL/6 mice (6-10 weeks old) were kindly provided by J. Tschopp (University of Lausanne, Swizterland) and B. Ryffel (University of Orleans, France). Pik3cd D910A were kindly provided by B. Vanhaesebrouck (Queen Mary University London). To generate mice lacking Syk specifically in DCs, Cd11cCre mice were crossed to Sykb fl/fl mice (unpublished observations). Bone marrow of these mice was used to generate chimeric mice, by sublethally irriaditing C57BL/6 mice (5Gy), followed 4 hr later by intravenous (i.v.) injection of 2 3 10 6 BM cells. Chimeric mice were used 10 weeks after hematopoietic reconstitution. All experiments were approved by the animal ethics committee at Ghent University and Erasmus University Medical Center.
Monosodium Urate Crystal Preparation MSU crystals were prepared as described (Chen et al., 2006) . In brief, saturated uric acid (5 mg/mL, Sigma) in 0.1 M borate buffer (pH 8.5) was incubated at room temperature for 48 hr. After harvesting the crystals, they were washed with alcohol and acetone and air-dried for at least 2 days. Crystals were between 5 and 25 mm long and contained <0.005 EU/mL endotoxin.
Treatment with Uricase
For intraperitoneal injections, mice received 50 U of uricase (Sigma-Aldrich) or rasburicase (Sanofi-Synthelabo) in 100 ml PBS 5 min prior to injection of OVA+alum. For intrapulmonary administration, HDM was mixed with 10 U uricase and injected intranasally into 40 ml.
Induction of Allergic Airway Inflammation
To test the adjuvant properties of MSU crystals, mice were injected intraperitoneally (i.p.) with 10 mg of OVA (Worthington) mixed with increasing amounts of MSU crystals (1-7.5 mg in 500 ml). Mice were boosted i.p. on day 7 with OVA and challenged with OVA aerosols (Sigma, 1% for 30 min) on days 17-19. On day 20, mice were analyzed for the presence of Th2 cell-dependent eosinophilic airway inflammation.
To induce HDM-driven eosinophilic airway inflammation, anesthetized mice were administered intranasaly (i.n.) with 40 ml of house dust mite extracts (100 mg, Greer Laboratories) on day 0 and challenged on days 7-11 with HDM. On day 14, mice were sacrificed and different parameters were analyzed. Assessment of bronchial hyperreactivity and histological analysis of goblet cell hyperplasia was measured as described previously ).
Immune Analysis
To determine the degree of airway eosinophilia, bronchoalveolar lavages (BAL) were performed by injecting 1 ml of PBS containing 0.01 mM EDTA. Cells were stained with FITC anti-I-A d and I-E d , PE-labeled anti-Siglec F, PerCp-labeled anti-CD3 and anti-CD19, and APC-labeled anti-CD11c (all from BD Biosciences). Peritoneal inflammatory cells were stained as described (Kool et al., 2008b) . Data were collected on a FACS Aria II (Becton Dickinson) and were analyzed with FlowJo software (Treestar, Inc.).
The concentration of UA (Amplex Red Uric Acid; Uricase assay, Invitrogen), GM-CSF, IL-33, TSLP, and IL-25 (all R&D Systems) was measured in BAL fluid and lung homogenates by ELISA 2 and 24 hr after HDM administration. The concentration of Th2 cytokines in BAL fluids was measured 24 and 72 hr after the last challenge, respectively.
OVA-specific IgG1, IgE, and IgG2a were measured in sera of mice sensitized and challenged with OVA by ELISA (antibodies from R&D Systems).
Uric Acid Staining in the Lung
Two hours after the i.n. administration of PBS or HDM, lungs were inflated with PBS and OCT and frozen at À80 C. Ten mm thick sections were fixed with 4%
formaline for 10 min and stained with rabbit anti-uric acid antibodies (Abcam) followed by Cy3-labeled goat anti-rabbit antibodies (Jackson Laboratories), blocking with rabbit serum, biotin-labeled anti-peroxisomal membrane protein 70 (Genetex), and FITC-labeled anti-MHCII (BD Bioscience), followed by streptavidin Alexa Fluor 647. Nuclei were counterstained with 4 0 ,6 0 diamidino-2-phenylindole (DAPI). Images were collected on a Zeiss LSM 710 equipped with a Ar 488 nm laser, a He-Ne 561 nm laser, a He-Ne 633 nm laser, and a Mai Tai femtosecond-pulsed laser tuned at 800 nm to excite DAPI. Images were analyzed with Imaris (Bitplane). 
